A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Public ClinicalTrials.gov record NCT03948763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
Study identification
- NCT ID
- NCT03948763
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 70 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2019 (Actual)
- Primary completion
- Aug 25, 2022 (Actual)
- Completion
- Aug 25, 2022 (Actual)
- Last update posted
- Jan 28, 2025
2019 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 1008) | Gilbert | Arizona | 85234 | — |
| City of Hope ( Site 1002) | Duarte | California | 91010 | — |
| University of California at San Francisco ( Site 1006) | San Francisco | California | 30322 | — |
| Smilow Cancer Hospital at Yale New Haven ( Site 1005) | New Haven | Connecticut | 06510 | — |
| Dana-Farber Cancer Institute (Boston) ( Site 1007) | Boston | Massachusetts | 02215 | — |
| Comprehensive Cancer Centers of Nevada ( Site 1012) | Las Vegas | Nevada | 89169 | — |
| Tennessee Oncology Nashville Drug Development Unit ( Site 7000) | Nashville | Tennessee | 37203 | — |
| START San Antonio ( Site 1004) | San Antonio | Texas | 78229 | — |
| Baylor Scott & White Medical Center - Temple ( Site 1009) | Temple | Texas | 76508 | — |
| Northwest Medical Specialties, PLLC ( Site 1001) | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03948763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03948763 live on ClinicalTrials.gov.